Lung adenocarcinoma invasion in TGFβRII-deficient cells is mediated by CCL5/RANTES

Oncogene

Volumn 27, Issue 4, 2008, Pages 557-564

  Borczuk, A C ^a   Papanikolaou, N ^a   Toonkel, R L ^a   Sole, M ^a   Gorenstein, L A ^a   Ginsburg, M E ^a   Sonett, J R ^a   Friedman, R A ^a   Powell, C A ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Bronchioloalveolar carcinoma; Disease progression; Lungad enocarcinoma; Neoplasm invasiveness; RANTES; TGF

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MET RANTES; RANTES; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL;

EID: 38349028584     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210662     Document Type: Article

References (24)

1. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M et al. (2002). The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62: 1093-1102.
2. Balkwill F. (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
3. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS et al. (2004). Transformingg rowth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 64: 4687-4692.
4. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA. (2005). Lunga denocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 172: 729-737.
5. Borczuk AC, Powell CA. (2007). Expression profilingand lung cancer development. Proc Am Thorac Soc 4: 127-132.
6. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. (2001). The new world health organization classification of lung tumours. Eur Respir J 18: 1059-1068.
7. Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN et al. (2006). Role of CCL5 (RANTES) in viral lung disease. J Virol 80: 8151-8157.
8. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI et al. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170-1172.
9. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR et al. (2005). Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65: 2296-2302.
10. Gupta GP, Massague J. (2006). Cancer metastasis: building a framework. Cell 127: 679-695.
11. Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR et al. (2004). Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. Am J Physiol Cell Physiol 286: C547-C555.
12. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S et al. (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transformingg rowth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20: 3147-3160.
13. Jang SB, Won J, Kim H, Kim J, Lee KH, Han H et al. (2002). TAK1 mediates lipopolysaccharide-induced RANTES promoter activation in BV-2 microglial cells. Mol Cells 14: 35-42.
14. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B et al. (1999). Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681-4687.
15. Ma B, Kang MJ, Lee CG, Chapoval S, Liu W, Chen Q et al. (2005). Role of CCR5 in IFN-gamma-induced and cigarette smoke-induced emphysema. J Clin Invest 115: 3460-3472.
16. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE et al. (2002). RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 8: 3803-3812.
17. Nakazaki Y, Hase H, Inoue H, Beppu Y, Meng XK, Sakaguchi G et al. (2006). Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther 14: 599-606.
18. Nissinen R, Leirisalo-Repo M, Tiittanen M, Julkunen H, Hirvonen H, Palosuo T et al. (2003). CCR3, CCR5, interleukin 4, and interferon-gamma expression on synovial and peripheral T cells and monocytes in patients with rheumatoid arthritis. J Rheumatol 30: 1928-1934.
19. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE et al. (1996). Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271: 2599-2603.
20. Remmelink M, Mijatovic T, Gustin A, Mathieu A, Rombaut K, Kiss R et al. (2005). Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lungcancers as compared to normal bronchial epithelial tissue. Int J Oncol 26: 247-258.
21. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Maeshima AM et al. (2004). Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 28: 198-206.
22. Schwabe RF, Bataller R, Brenner DA. (2003). Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285: G949-G958.
23. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. (2006). Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66: 124-134.
24. van Deventer HW, O'Connor Jr W, Brickey WJ, Aris RM, Ting JP, Serody JS. (2005). C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 65: 3374-3379.